ACM
KYMR icon

Accent Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Accent Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.2K Buy
351
+41
+13% +$3.52K 0.02% 120
2026
Q1 		$25.8K Buy
310
+160
+107% +$12.7K 0.01% 144
2025
Q4 		$11.7K Buy
+150
New +$10.1K 0.01% 177
2025
Q3 		– Sell
-62
Closed -$2.71K – 404
2025
Q2 		$2.71K Buy
+62
New +$2.13K ﹤0.01% 376

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Accent Capital Management's KYMR Position: Q2 2026 in Review

Accent Capital Management increased its Kymera Therapeutics (KYMR) stake by 13% in Q2 2026, buying an estimated $3.52K and bringing the position to 351 shares worth $40.2K. The position accounts for 0.02% of the portfolio, ranked #120.

Accent Capital Management first reported a position in KYMR in Q2 2025 and has held it in 4 quarters since. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Accent Capital Management held 351 shares of Kymera Therapeutics worth $40.2K as of Q2 2026.
  • Accent Capital Management bought 41 Kymera Therapeutics shares in Q2 2026, an estimated $3.52K.
  • Kymera Therapeutics made up 0.02% of Accent Capital Management's portfolio in Q2 2026, its #120 holding.
  • Accent Capital Management first reported a position in Kymera Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Accent Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.